Oncology Times immunotherapy, NSCLC, ASCOrewind: 05/12/2021 14:30:13
#Researchers have reported for the first time that an #immunotherapy agent has extended disease-free survival in patients with early-stage #NSCLC: https://t.co/MBUNg7MTqH #ASCOrewind
.@LealTiciana, of @WinshipAtEmory, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer #lcsm
Findings showed that the median PFS with the novel sintilimab combination regimen was 6.9 months per IRRC assessment vs 4.3 months with chemotherapy alone. #lcsm #oncology https://t.co/GJLM5NUNnY
